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Immunogenicity and safety
of a live attenuated varicella
vaccine in healthy Indian
children aged 9 - 24 months
A. Ramkissoon, H. M. Coovadia, P. Jugnundan,
I. E. Haffejee, F. Meurice, D. Vandevoorde
Objectives. To investigate the safety of live attenuated
varicella vaccine (aka strain) and the optimal virus titre/
dose required for immunogenicity in healthy South African
children.
Design. Double-blind randomised clinical study using
two different lots of varicella vaccine, each at two different
titres. Subjects were randomly allocated to groups 1, 2, 3
and 4 to receive vaccine containing a mean virus titre of
10"', 103,1, 103•9 and 102,7 PFUs per dose respectively.
Clinical signs and symptoms were followed up for 42 days
post-vaccination. Specific varicella antibodies were
measured by an indirect immunofluorescence method in
sera obtained on day 0 and day 42.
Setting. City Health Clinic, Chatsworth, Durban.
Participants. A total of 200 healthy 9 - 24-month-old
children were vaccinated, of whom 189 (44,5%) completed
the study.
Main outcome measures. Pre- and post-vaccination
varicella antibody levels. Adverse events following
varicella vaccination..
Results. The vaccine was safe and well tolerated. No
local symptoms were reported. Skin reactions were
specifically solicited in this study: 21 reactions were
reported in 8,5% (17/200) of children. Vesicles were
reported in 2 vaccines (,,;: 10 vesicles in both cases). One
serious adverse event was reported: hospitalisation for
bronchopneumonia on day 16 post-vaccination which
resolved without sequelae. Around day 42 post-
vaccination (range 35 - 63 days) all the 176 initially
seronegative subjects had seroconverted for varicella
antibodies. Post-vaccination geometric mean titres (GMTs)
were 104,1, 66,2, 69,5 and 77,0 for groups 1 - 4
respectively. Six subjects who were initially seropositive
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maintained or increased their titres post-vaccination; 3 of
the 6 showed a booster response (a ;:;, 4-fold increase
from the pre-vaccination titre).
Conclusions. Varicella vaccine was found to be safe,
immunogenic and well tolerated. No difference in
seroconversion rates or GMTs, either between groups
receiving the two vaccine lots or between groups receiving
the different titres of each lot, was shown.
S Afr Med J 1995; 85: 1295-1298.
The inclusion of different vaccines in routine vaccination
schedules is under serious scrutiny as new vaccines
become available. A live attenuated varicella vaccine (Oka
strain) was developed in Japan in the early 1970s and is
currently being used in many countries for the prevention of
varicella in high-risk and immunocompromised children.'
Although not registered in South Africa, the vaccine (Varilrix;
SmithKline Beecham Biologicals) is available for the above
purpose and has been used in Belgium and other European
countries since 1984.
In Japan and South Korea, the same Oka strain is used in
a vaccine licensed for general vaccination of all healthy
children at an early age, and more than 1 million doses have
been administered since 1986.
In South Africa, chicken-pox is not a notifiable disease,
and there is therefore a paucity of morbidity and mortality
data. The disease is widely recognised to be present,
although the vast majority of cases are not hospitalised. In a
study of 244 healthy adults in South Africa, the overall level
of immunity to varicella was found to be 90%.'
The inclusion of varicella vaccine in routine vaccination
schedules in South Africa would result in the protection of
both healthy and high-risk children and have considerable
advantages. These include prevention of the complications
of varicella (e.g. encephalitis, pneumonia, scars); inhibition of
the spread of the disease, particularly in institutions; a
possible reduction of the incidence and/or severity of zoster
in later life; and cost-benefits of reduced morbidity in the
population, e.g. the need for a working parent to remain
home with a sick child.
Varicella vaccine has not been evaluated previously in
South Africa. The present study was undertaken to evaluate
in healthy babies aged 9 - 24 months the safety and
immunogenicity of two different lots of varicella vaccine and
to evaluate the safety and immunogenicity of a 'fresh'
vaccine (soon after manufacture) and a vaccine at a lower
titre (artificially obtained by exposure at 3JOC for 7 - 10
days). The latter was thought to mimic prolonged storage
conditions at refrigerator temperatures, since continuity
of a 'cold chain' is not always maintained in developing




Varilrix was the live attenuated varicella vaccine (Oka strain)
used in this study. Two untreated 'fresh' vaccine lots (VA 101
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A42 and VA 104 842) were used, as well as vials of these
two lots exposed at 3rC for 10 and 7 days respectively
(which reduced the initial virus titre). The mean virus
titres/doses (PFUs) received by subjects in groups 1 - 4
respectively were 104 ,5 (high titre), 103,1 (Iow titre), 1039 (high
titre) and H)2-' (Iow titre). The vaccines were supplied in
monodose vials, each was reconstituted with an individual
ampoule of water for injection and one 0,5 ml dose was
administered subcutaneously into the left upper arm.
Subjects
The subjects were 200 healthy Indian boys and girls 9 - 24
months (mean 15,9 months) residing in Chatsworth, Durban.
Exclusion criteria included history of clinical varicella
infection, recent exposure to var,icella or zoster, recent
administration of immunoglobulins, adverse reactions to
previous vaccination, or other vaccination (except oral polio)
within 4 weeks. Prior to enrolment, children underwent
clinical examination and written.informed consent was
obtained from the parent or guardian. Subjects were
randomly allocated to 1 of 4 groups (groups 1, 2, 3, 4) in the
order in which they were enrolled in the study. One hundred
and eighty-nine of the 200 subjects (94,5%) completed the
study.
Study design
The study was approved by the Ethics Review Committee of
the Faculty of Medicine, University of Natal. On day 0,
subjects underwent physical examination, axillary body
temperature was recorded, a pre-vaccination blood sample
was collected and one dose of the vaccine was
administered. Parents were asked to observe the child for
any clinical signs or symptoms and were instructed to
contact the investigator immediately if any rash/eruption or
serious adverse event occurred. All parents were contacted
on day 21 to evaluate the presence of clinical signs and
symptoms. On day 42, a physical examination took place, a
post-vaccination blood sample was collected and the study
period was reviewed for any signs or symptoms. Any
medication received during the study period was also
recorded.
Serology
Separated pre- and post-vaccination serum samples (day 0
and day 42) were stored at -20°C. Specific varicella
antibodies were measured by an indirect
immunofluorescence method.3 Samples which showed no
fluorescence or barely visible fluorescence at the starting
dilution (1/4) were considered seronegative. The titre was
expressed as the reciprocal of the highest dilution still
shOWing a varicella/zoster virus-associated fluorescence.
Seroconversion was defined as the appearance of
antibodies in the serum of subjects who were seronegative
before vaccination (i.e. titre < 4 prior to vaccination to ? 4 in
post-vaccine serum). A booster response was defined as a
fourfold increase in a positive pre-vaccination titre.
Geometric mean titres (GMTs) of specific varicella antibodies
were calculated in post-vaccination sera in seroconverters
and in pre- and post-vaccination sera in the initially
seropositive subjects. GMTs were calculated by using the
log transformation of titres? 4 and then taking the antilog
of the mean of these transformed values. Analysis was
performed by SAS using a type I error (alpha) of 5%.
Immunogenicity
GMTs of specific varicella antibodies were calculated for
each group at the second time point of the study (day 42) in
seroconverters. Ninety-five per cent confidence intervals of
these GMTs were calculated. The percentage of
seroconverters was calculated for each group as defined
above. Ninety-five per cent confidence intervals of these
percentages were calculated. _.
Safety and reactogenicity
Skin reactions were solicited and the distribution and the
number of papules and/or vesicles observed were
described. Maculopapular rash, macular rash andjJapular
rash were grouped together as papular rashes, an:d
papulovesicular rash and vesicular rash were grouped
together as vesicular rashes. The observed unsolidted
clinical signs and symptoms were described and the
percentage of subjects reporting local and general
symptoms calculated for the follow-up period.
Results
Immunogenicity of the vaccine
A total of 182 subjects were included in the immunogenicity
analysis, of whom 176 were seronegative and 6 were
seropositive before vaccination. Eighteen subjects were
eliminated from the analysis: 6 for irregular schedule of visits
and 12 for a missing blood sample.
Table I shows the seroconversion rates and GMTsof
specific varicella antibodies at day 42 post-vaccination for
the 176 initially seronegative subjects. All these children had
detectable antibody titres post-vaccination. GMTs varied
from 66,1 to 104,1 among the four groups. Children below
18 months of age had GMTs (74; (95% Cl: 64,0 - 85,0))
comparable to those of children over 18 months (91; (95%
Cl: 71,2 -115,1)) (P = 0,144).
Table I. Percentage seroconversion and GMT of varicella
antibodies on day 42 post-vaccination in initially seronegative
subjects
% sero- GMT CL 95%t CL 95%t
Group' No. conversion . (titre range) lower upper
1 47 100,0 104,1 (16 - 1 024) 84,0 129,0
2 42 100,0 66,1 (8 - 512) 47,8 91,5
3 42 100,0 69,5 (8 - 512) 54,4 88,9
4 45 100,0 77,0 (32 - 512) 64,3 92,2
"Group 1, 2, 3 and 4 received vaccine containing 1cr.s, 1()1" 1Q1.9, 102-7 PFUs of
varicella virus per dose respectively.
t Lower and upper 95% GMT confidence limrts.
Six infants (2 each from groups 2,3 and 4) were initially
seropositive for specific varicella antibodies. All 6 children
maintained or increased their titre post-vaccination. There
were 3 booster reactions (defined as a fourfold or greater
increase in pre-vaccination titre), 2 in group 2 and 1 in group




Table 11. Skin reactions reported after vaccination
Vaccine groups
1 2 3 4 1 - 4
Skin reactions (N =50) (N = 51) (N = 50) (N =49) (N = 200)
Papular rashes· 2 2 4 1 9
Vesicular rashes· 1 1 2
Other skin reactions· 2 2 5 2 10
Any skin reactiont 4 reactions 4 reactions 9 reactions 4 reactions 21 reactions
in 2 subjects in 4 subjects in 8 subjects in 3 subjects in 17 subjects
• Figures indicate the number of times a reaction was reported.
t P = 0,21 (Fisher's exact test comparing number of subiects with skin reaction in each group).
4. Their post-/pre-titre ratios were 16, 64 and 16
respectively.
Reactogenicity
Signs and symptoms of any kind were reported during the
42-day follow-up period in 22,5% of subjects (46/200) -
22% in group 1, 19,6% in group 2, 28% in group 3 and
20,4% in group 4; all reported symptoms were general, and
no symptoms were reported at the injection site.
Skin reactions were specifically solicited in this study.
Twenty-one skin reactions were reported in 8,5% of subjects
(17/200): 4%, 7,8%,16% and 16,1% in groups 1 - 4
respectively. Vesicles were reported in only 2 subjects (10
vesicles or fewer in both cases): 1 in group 1 and 1 in group
4. Mild, attenuated chicken-pox was clinically diagnosed in
the subject from group 4 on day 16; fever and bilateral
conjunctivitis were also reported in this subject. He was
initially seronegative and had a post-vaccination titre of 32.
Details of reported skin reactions are given in Table 11.
Sixty-three unsolicited symptoms (including fever, gastro-
intestinal disorders, respiratory infections, measles and
conjunctivitis) were reported in 20,5% (41/200) of subjects:
20% in group 1, 21,6% in group 2, 16% in group 3 and
24,5% in group 4. One symptom was assessed by the
investigator as 'possibly related' (fever in a subject in
group 4). Only one serious adverse event was reported:
bronchopneumonia in a subject in group 2 on day 16 post-
vaccination; he was hospitalised and recovered without
sequelae. This event was considered to be unrelated to
varicella vaccination.
Discussion
Varicella vaccine (Oka strain) has been given to over 10 000
healthy individuals and patients with a variety of diseases in
well-controlled trials held since the 1970s. They showed that
the Oka strain was attenuated, stable and tended not to
return to virulence, that'all the vaccines gave a similar high
level of immunogenicity, and that all were equally well
tolerated.'" Despite this, varicella vaccine is not in routine
use in most countries. The reason for this is that certain lots
of the vaccine given to leukaemic children resulted in a high
incidence of often severe vaccine-associated chicken-pox.'
These lots were subsequently found to contain 'less
attenuated' virus which may have resulted in an altered host
immune response. Clinical trials with new lots have since
been undertaken and licensing and widespread use of the
vaccine are now imminent in the USA and several European
countries.
Another major concern about varicella vaccine has been
whether there would be an increased risk of shingles (zoster)
in immunised children. Studies in the USA have shown that
the rate of zoster was lower than that expected after natural
chicken-pox in both healthy and leukaemic children.5.•
The primary objective of the present study was to evaluate
the immunogenicity and reactogenicity of two different lots
of varicella vaccine and to compare their immunogeoicity at
two different potencies; release titre (high: 10•.5- 103.") and
expected expiry titre (Iow: 10'·1 - 10"'), Le. a range of
31 623 - 501 PFUs/dose. Vaccine doses containing 500 to
1 000 PFUs, have been shown to be immunogenic in > 90%
of children and adults 3 Reviews of varicella vaccine trials
involVing vaccines ranging from 400 to '30 000 PFUs per
dose showed similar high levels of immunogenicity and
safety for all the vaccines and indicated that the attenuated
Oka strain is phenotypically and genetically stable. There
was no evidence of any tendency to revert to virulence;
however, lower rates of seroconversion were seen with lower
doses of vaccine.
This study provides sufficient evidence that this varicella
vaccine is safe, immunogenic and well tolerated in young
South African children, as was found to be the case in
similar studies with several Oka strain vaccines in Japan, the
USA and Turkey."]'·
The results of this study confirm findings elsewhere that
the rate of seroconversion is generally greater than 95% in
healthy subjects after one dose of varicella vaccine.'·5.]
The 200 children aged 9 - 24 months who received one
subcutaneous injection of this Oka strain varicella vaccine
showed excellent tolerance of the vaccine and all initially
seronegative subjects had seroconverted for varicella
antibodies by day 42. Only 6 subjects (3%) in the study
population were seropositive for varicella before vaccination
and they were over 12 months of age. Of the 24 other
subjects who were younger than 12 months of age, all were
initially seronegative for varicella antibodies. These data
suggest that most might have lost any maternally derived
immunity by the time they were 9 - 12 months old. At this
early stage, when the majority of infants are seronegative
and therefore likely to be susceptible to varicella, the
vaccine used was thus shown to be safe, well tolerated and
to elicit an extremely satisfactory immune response.
Varicella vaccine appears to be highly effective in
protecting healthy children against infection. Mild
breakthrough cases of varicella occasionally occur months
or years after vaccination," but the vaccinees are indeed
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protected against varicella cases of clinical relevance.
During the more than 15-year follow-up of vaccinated
children in Japan and the 7-year follow-up of those in the
USA, the protection conferred by the vaccine appeared to
be long-Iasting."a The duration of protection needs, however,
to be examined further before the need for booster doses
can be assessed properly.
Live vaccines are heat-sensitive and may therefore be
subject to loss of potency following breaks in the 'cold
chain', a common occurrence in developing countries.
Different vaccine viral titres were used to investigate the
response to lower titres obtained after exposure at 3rC for
several days produced a titre mimicking prolonged storage
conditions in a refrigerator. The two vaccine lots as well as
the different titres used in this study all induced 100%
seroconversion. These results allow for less stringent
storage conditions than previously recommended (Le.
refrigerator as compared to freezer) for this vaccine. The
stability of this vaccine compared with the currently available
commercial varicella vaccine has been demonstrated in 'real
time stability' in vitro studies with vaccine stored at 4°C; the
stability was not demonstrated as such in this study,
however.
Preliminary studies have shown that varicella vaccine is
safe in adults and in both healthy and leukaemic children,
with few reported adverse reactions.,,3,. The only significant
reactions which have been described elsewhere and these
only rarely (in 5 - 10% of vaccinees) are mild fever and skin
rashes with occasional vesicles by no means comparable in
number and distribution to those seen during natural
chicken-pox.
In our study, skin reactions were reported in 8,5% of
subjects (Table 11). Most of these were mild maculopapular
rashes (1 - 10 spots). Skin reactions were not reported at
significantly different rates between groups or titres
(P =0,21; Fisher's exact test). Only 2 children had vesicles
(10 or fewer in both cases): 1 of these 2 was clinically
diagnosed with a mild, attenuated chicken-pox that
appeared 17 days after vaccination with fever and bilateral
conjunctivitis; however, her post-vaccination titre was only
32 which is very low when compared with titres (generally
;;. 512) induced by natural varicella in non-vaccinees.
No parent or guardian reported any local sign or symptom
at the injection site and three-quarters of them did not
mention any symptoms at all during the 42-day study
period. Among those who did, the symptoms were mild and
distributed almost equally in the 4 groups of vaccinees. The
fact that the incidence of severe post-vaccination events
following varicella vaccine is minimal further justifies the
prevention of this relatively mild childhood disease by
vaccination.
In a recent conservative cost-benefit analysis in the USA,
routine varicella vaccination at US$35/dose has been shown
to be cost-effective for both healthy and leukaemic children
when given as a combined vaccine with MMR as part of the
routine vaccination schedule.'o As a follow-up to this study,
our results allow for further studies to investigate the
possibility that varicella vaccine could be simultaneously
administered with measles vaccine since, in South Africa,
the latter is routinely administered to infants aged 9 - 10
months, and again at 15 months (mean age of infants in this
study).
The South African National Advisory Group on
Immunisation has recently determined infectious disease
immunisation priorities in this country to be hepatitis Band
Haemophilus influenzae type B followed by the
pneumococcal pneumonias. While not a priority at present,
when financial resources become available, routine varicella
vaccination of all children in South Africa will have
considerable advantages. Although most varicella infections
are benign and serious morbidity is infrequent, the disease is
highly contagious and leads to interruption of children's
attendance at school and disturbs the organisation at
creches and preschools. The necessity for home care -can
have significant effects on the parents' working life, and
routine vaccination is therefore likely to be cost-effective.
Other advantages of varicella vaccination include the
prevention of complications (pneumonia, encephalitis,
scars), inhibition of the spread of institutional outbjeaks and
thus the diminishing of exposure of high-risk subjects to the
disease; a possible reduction in the occurrence and/or
severity of zoster in later Iife'Q-12 is also likely. Altho~gh not
registered in South Africa at present Varilrix is currently
being used in many countries for the prevention of varicella
in high-risk and immunocompromised children.
General varicella vaccination of South African children
seems an attractive prospect to prevent the normal
morbidity of chicken-pox; however, until finances become
available, we recommended that it be administered routinely
to 'high-risk' non-immune children (e.g. those with malignant
disease) and to institutionalised children.
We would like to thank City Health, Durban (especially the
staff of Unit 6 Clinic, Chatsworth) and SmithKline Beecham
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